@alkpositive.bsky.social🎥 The ALKtALK replay is now available!
What’s new in ALK-positive cancer research, and what could it mean for you?
Dr. Ken Culver shares clinical trial updates, emerging research, and a preview of our November Lung Cancer Awareness Month campaign! đź’š
▶️ Watch: youtu.be/r3ocrSEb-jc
@alkpositive.bsky.socialWhat does survivorship mean when living with ALK-positive cancer?
In this ALKtALK clip, Dr. Eric Singhi shares why survivorship goes beyond treatment to include quality of life, adapting, and living well.
🎥 Watch the full replay: youtu.be/aIVlb1OiWxU
@alkpositive.bsky.socialALKtALK Season 7 premieres Sunday, Sept. 27 at 7 p.m. ET with Dr. Eric Singhi (@lungoncdoc) of MD Anderson. Join us on Zoom for WCLC updates, practical information for life with ALK-positive cancer, and live Q&A.
@alkpositiveuk.bsky.socialCould alectinib be used before surgery for ALK+ #lungcancer?
In the phase 2 NAUTIKA1 study, 55.8% had a major pathological response after 8 weeks of alectinib before surgery.
It’s early research, but an interesting new direction for ALK+ treatment.
@alkpositiveuk.bsky.socialScotland has confirmed routine NHS access to lorlatinib after previous ALK+ lung cancer treatment.
It had been available on an interim basis since 2020. Following reassessment and further evidence, that access is now routine.
@alkpositiveuk.bsky.socialNew research is helping us understand why ALK targeted treatments can stop working.
In 148 people with ALK+ #lungcancer, researchers identified changes in the RAS pathway as one possible route of resistance.
An important clue for future research.